UA91283U - Drug formulation possessing pronounced antigestagenic activity - Google Patents
Drug formulation possessing pronounced antigestagenic activityInfo
- Publication number
- UA91283U UA91283U UAU201401316U UAU201401316U UA91283U UA 91283 U UA91283 U UA 91283U UA U201401316 U UAU201401316 U UA U201401316U UA U201401316 U UAU201401316 U UA U201401316U UA 91283 U UA91283 U UA 91283U
- Authority
- UA
- Ukraine
- Prior art keywords
- drug formulation
- antigestagenic activity
- formulation possessing
- pronounced antigestagenic
- possessing pronounced
- Prior art date
Links
- 230000000380 anti-gestagenic effect Effects 0.000 title abstract 2
- 239000013583 drug formulation Substances 0.000 title abstract 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- 229920002472 Starch Polymers 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 abstract 1
- 235000013539 calcium stearate Nutrition 0.000 abstract 1
- 239000008116 calcium stearate Substances 0.000 abstract 1
- 238000007907 direct compression Methods 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 235000019359 magnesium stearate Nutrition 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 235000019698 starch Nutrition 0.000 abstract 1
- 239000008107 starch Substances 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
A drug formulation containing one or more dosage units of the Mifepriston-based pharmaceutical composition possessing the pronounced antigestagenic activity contains the active ingredient and the excipients, namely microcrystalline cellulose, sodium carboxymethyl starch, and calcium stearate or magnesium stearate. The said dosage form is manufactured by the direct compression of the tablets.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UAU201401316U UA91283U (en) | 2014-02-10 | 2014-02-10 | Drug formulation possessing pronounced antigestagenic activity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UAU201401316U UA91283U (en) | 2014-02-10 | 2014-02-10 | Drug formulation possessing pronounced antigestagenic activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA91283U true UA91283U (en) | 2014-06-25 |
Family
ID=56283041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAU201401316U UA91283U (en) | 2014-02-10 | 2014-02-10 | Drug formulation possessing pronounced antigestagenic activity |
Country Status (1)
| Country | Link |
|---|---|
| UA (1) | UA91283U (en) |
-
2014
- 2014-02-10 UA UAU201401316U patent/UA91283U/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ721298A (en) | Pharmaceutical compositions comprising azd9291 | |
| MX371432B (en) | Tamper-resistant dosage form containing one or more particles. | |
| EP4349406A3 (en) | Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole for use as a medicament | |
| PH12020550815A1 (en) | Delayed release deferiprone tablets and methods of using the same | |
| MX377955B (en) | IMMEDIATE-RELEASE TABLETS CONTAINING A DRUG AND PROCESSES FOR FORMING THE TABLETS | |
| MX2020002310A (en) | High concentration dosage forms of pridopidine. | |
| MY194278A (en) | Pharmaceutical composition | |
| MY205197A (en) | Methyllactam ring compound and pharmaceutical use thereof | |
| EA202090913A1 (en) | COMPOSITION OF MODIFIED RELEASE TABLETS CONTAINING MIRABEGRON | |
| PH12016500120A1 (en) | Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation | |
| MX2018010065A (en) | Oral dosage form comprising rifaximin in form beta. | |
| TW201613580A (en) | Ceritinib formulation | |
| SA516370446B1 (en) | Anti-tuberculosis stable pharmaceutical composition in a form of a dispersible tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation | |
| UA91283U (en) | Drug formulation possessing pronounced antigestagenic activity | |
| MX2017000384A (en) | Capsule dosage form of metoprolol succinate. | |
| UA91281U (en) | Method for manufacturing drug formulation possessing pronounced antigestagenic activity | |
| PH12019501260A1 (en) | A fast disintegrating pharmaceutical composition | |
| EA201600242A1 (en) | PHARMACEUTICAL COMPOSITION IN THE FORM OF A TABLET AND METHOD FOR ITS PREPARATION | |
| PH12020500295A1 (en) | Pharmaceutical composition for prevention or treatment of cardiovascular diseases accompanied by diabetes, including amlodipine, losartan, and rosuvastatin, and composite preparation including the same | |
| MX2019005005A (en) | Extended release tablet comprising a weight-loss drug. | |
| UA97982U (en) | DRESSING MEDICINE FOR TABLETS | |
| UA120295U (en) | ANTI-THROMBOCITARY ACTION MEDICINAL PRODUCT | |
| UA91282U (en) | Drug formulation possessing pronounced antigestagenic activity | |
| PH12020550597A1 (en) | Formulation having improved hygroscopic property and dissolution rate comprising telmisartan or its pharmaceutically acceptable salt | |
| EA202090842A1 (en) | DEFERIPRONE DELAYED RELEASE TABLETS AND METHODS OF THEIR USE |